Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 150mg. Distribution of the product has commenced.
The details can be read here.
Also IMPAX and WATSON has received approval from USFDA to market Wellbutrin XL 150mg.
No comments:
Post a Comment